141W94/VX-478 HIV protease inhibitor: VRTX and partner Glaxo Wellcome plc began a double-blind Phase III trial of 141W94 in combination with nucleoside analog t

Patients will continue to receive their other therapy and in addition will receive either placebo or

Read the full 169 word article

How to gain access

Continue reading with a
two-week free trial.